



SHAREABLE PDF

Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers

Duncan Keeley¹, Jane E. Scullion ² and Omar S. Usmani³

Affiliations: ¹Thame, UK. ²University Hospitals of Leicester NHS Trust, Leicester, UK. ³National Heart and Lung Institute, Imperial College London, London, UK.

Correspondence: Omar S. Usmani, Imperial College London and Royal Brompton Hospital, National Heart and Lung Institute (NHLI), Airways Disease Section, Dovehouse Street, London SW3 6LY, UK. E-mail: o.usmani@imperial.ac.uk

 @ERSpublications

The greenest inhaler is an appropriately prescribed device, that the patient has been properly taught and assessed how to use, is happy with and most important of all, gives them clinical benefit <https://bit.ly/2VKicQW>

Cite this article as: Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. *Eur Respir J* 2020; 55: 2001122 [<https://doi.org/10.1183/13993003.01122-2020>].

This single-page version can be shared freely online.

From the authors:

We thank L. Lehtimäki and colleagues for their letter, and acknowledge and apologise for the error they identify relating to the country of the study [1]. All respiratory inhaled treatments are a combination of the drug and device, and we cited the Icelandic study to illustrate that an enforced switch of treatment by the government, here to low-cost alternatives, led to poorer clinical outcomes [1]. In this context, the mandated recommendations of the UK government for environmental reasons, give cause for concern. Our editorial stresses the necessity for patient engagement and choice, as well as clinical efficacy, to be considered in all steps of inhaler prescribing.